Department of Ambulatory Care and Community Medicine, University of Lausanne, Bugnon 44, 1011 Lausanne, Switzerland.
JAMA. 2010 Sep 22;304(12):1365-74. doi: 10.1001/jama.2010.1361.
Data regarding the association between subclinical hypothyroidism and cardiovascular disease outcomes are conflicting among large prospective cohort studies. This might reflect differences in participants' age, sex, thyroid-stimulating hormone (TSH) levels, or preexisting cardiovascular disease.
To assess the risks of coronary heart disease (CHD) and total mortality for adults with subclinical hypothyroidism.
The databases of MEDLINE and EMBASE (1950 to May 31, 2010) were searched without language restrictions for prospective cohort studies with baseline thyroid function and subsequent CHD events, CHD mortality, and total mortality. The reference lists of retrieved articles also were searched.
Individual data on 55,287 participants with 542,494 person-years of follow-up between 1972 and 2007 were supplied from 11 prospective cohorts in the United States, Europe, Australia, Brazil, and Japan. The risk of CHD events was examined in 25,977 participants from 7 cohorts with available data. Euthyroidism was defined as a TSH level of 0.50 to 4.49 mIU/L. Subclinical hypothyroidism was defined as a TSH level of 4.5 to 19.9 mIU/L with normal thyroxine concentrations.
Among 55,287 adults, 3450 had subclinical hypothyroidism (6.2%) and 51,837 had euthyroidism. During follow-up, 9664 participants died (2168 of CHD), and 4470 participants had CHD events (among 7 studies). The risk of CHD events and CHD mortality increased with higher TSH concentrations. In age- and sex-adjusted analyses, the hazard ratio (HR) for CHD events was 1.00 (95% confidence interval [CI], 0.86-1.18) for a TSH level of 4.5 to 6.9 mIU/L (20.3 vs 20.3/1000 person-years for participants with euthyroidism), 1.17 (95% CI, 0.96-1.43) for a TSH level of 7.0 to 9.9 mIU/L (23.8/1000 person-years), and 1.89 (95% CI, 1.28-2.80) for a TSH level of 10 to 19.9 mIU/L (n = 70 events/235; 38.4/1000 person-years; P <.001 for trend). The corresponding HRs for CHD mortality were 1.09 (95% CI, 0.91-1.30; 5.3 vs 4.9/1000 person-years for participants with euthyroidism), 1.42 (95% CI, 1.03-1.95; 6.9/1000 person-years), and 1.58 (95% CI, 1.10-2.27, n = 28 deaths/333; 7.7/1000 person-years; P = .005 for trend). Total mortality was not increased among participants with subclinical hypothyroidism. Results were similar after further adjustment for traditional cardiovascular risk factors. Risks did not significantly differ by age, sex, or preexisting cardiovascular disease.
Subclinical hypothyroidism is associated with an increased risk of CHD events and CHD mortality in those with higher TSH levels, particularly in those with a TSH concentration of 10 mIU/L or greater.
关于亚临床甲状腺功能减退症与心血管疾病结局之间的关系,大型前瞻性队列研究的结果存在差异。这可能反映了参与者的年龄、性别、促甲状腺激素(TSH)水平或已有心血管疾病的差异。
评估亚临床甲状腺功能减退症成年人的冠心病(CHD)和总死亡率风险。
从 MEDLINE 和 EMBASE 数据库(1950 年至 2010 年 5 月 31 日)中检索前瞻性队列研究,这些研究具有基线甲状腺功能和随后的 CHD 事件、CHD 死亡率和总死亡率数据,检索时没有语言限制。还检索了检索到的文章的参考文献列表。
从美国、欧洲、澳大利亚、巴西和日本的 11 个前瞻性队列中提供了 55287 名参与者的个人数据,这些参与者在 1972 年至 2007 年期间随访了 542494 人年。在有可用数据的 7 个队列中,有 25977 名参与者检查了 CHD 事件的风险。甲状腺功能正常定义为 TSH 水平为 0.50 至 4.49 mIU/L。亚临床甲状腺功能减退症定义为 TSH 水平为 4.5 至 19.9 mIU/L,甲状腺素浓度正常。
在 55287 名成年人中,3450 人患有亚临床甲状腺功能减退症(6.2%),51837 人甲状腺功能正常。随访期间,9664 名参与者死亡(2168 人死于 CHD),4470 名参与者发生 CHD 事件(在 7 项研究中)。随着 TSH 浓度的升高,CHD 事件和 CHD 死亡率的风险增加。在年龄和性别调整分析中,TSH 水平为 4.5 至 6.9 mIU/L(甲状腺功能正常参与者为 20.3 比 20.3/1000 人年)的参与者中,CHD 事件的危险比(HR)为 1.00(95%置信区间[CI],0.86-1.18),TSH 水平为 7.0 至 9.9 mIU/L(23.8/1000 人年)的参与者为 1.17(95%CI,0.96-1.43),TSH 水平为 10 至 19.9 mIU/L(n = 70 例/235 例;38.4/1000 人年;P <.001 趋势)。CHD 死亡率的相应 HR 为 1.09(95%CI,0.91-1.30;甲状腺功能正常参与者为 5.3 比 4.9/1000 人年),1.42(95%CI,1.03-1.95;6.9/1000 人年),1.58(95%CI,1.10-2.27,n = 28 例/333 例;7.7/1000 人年;P =.005 趋势)。亚临床甲状腺功能减退症患者的总死亡率没有增加。进一步调整传统心血管危险因素后,结果相似。风险在年龄、性别或已有心血管疾病方面没有显著差异。
在 TSH 水平较高的患者中,亚临床甲状腺功能减退症与 CHD 事件和 CHD 死亡率风险增加相关,尤其是 TSH 浓度为 10 mIU/L 或更高的患者。